Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand.
Am J Clin Dermatol. 2013 Feb;14(1):61-4. doi: 10.1007/s40257-012-0004-6.
Vismodegib is the first Hedgehog pathway inhibitor to be approved in the USA, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. In an ongoing, noncomparative, phase II trial, oral vismodegib was effective in and had an acceptable tolerability profile in the treatment of patients with locally advanced or metastatic BCC.
威莫司汀是首个在美国获得批准的 Hedgehog 通路抑制剂，用于治疗转移性基底细胞癌（BCC）的成人患者，或用于手术治疗后复发、不适合手术或不适合放疗的局部晚期 BCC 患者。在一项正在进行的、非对照的 II 期试验中，口服威莫司汀在治疗局部晚期或转移性 BCC 患者中有效，且耐受性可接受。
